46122TAA0
Precigen Inc
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company in Germantown, Maryland, that develops gene and cell therapies for hard-to-treat diseases like cancer and autoimmune conditions. Its platforms include UltraCAR-T, a method of building CAR-T cell treatments in about a day, and AdenoVerse, which delivers immunotherapies using engineered viruses. Precigen began in 2019 as a subsidiary of the synthetic-biology firm Intrexon, and in 2020 the parent company shed its energy and agriculture businesses, renamed itself Precigen, and pivoted to focus purely on human health.
CONVERTIBLEUnderlying: XONCUSIP: 46122TAA0HealthcareUS2 derivative reporters
3.5% Convertible Note due 07/01/2023
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
Note/bond (principal)